{"log_id": 1204875861856175070, "direction": 0, "words_result_num": 26, "words_result": [{"probability": {"variance": 2.2e-05, "average": 0.996137, "min": 0.985795}, "location": {"width": 171, "top": 237, "height": 30, "left": 191}, "words": "【药物相互作用】)"}, {"probability": {"variance": 3e-06, "average": 0.998383, "min": 0.995633}, "location": {"width": 94, "top": 295, "height": 30, "left": 180}, "words": "特殊人群"}, {"probability": {"variance": 6.5e-05, "average": 0.996192, "min": 0.966904}, "location": {"width": 697, "top": 340, "height": 41, "left": 226}, "words": "老人用药:老年患者无需调整剂量(见【老年用药】和【药代动力学】)"}, {"probability": {"variance": 0.000125, "average": 0.996504, "min": 0.945754}, "location": {"width": 801, "top": 395, "height": 41, "left": 226}, "words": "肾损害:目前尚未进行阿昔替尼在肾损害患者中的试验。根据群体药代动力学分析"}, {"probability": {"variance": 0.005485, "average": 0.980291, "min": 0.577344}, "location": {"width": 848, "top": 449, "height": 42, "left": 179}, "words": "结果,观察到阿昔替尼在轻度至重度肾损害患者中的清除率无显著差异(15mL/mins"}, {"probability": {"variance": 0.000112, "average": 0.994204, "min": 0.943246}, "location": {"width": 847, "top": 503, "height": 43, "left": 180}, "words": "肌酐清除率[CLcr]<89mL/min)(见【药代动力学】)。轻度至重度肾损害患者无需调整"}, {"probability": {"variance": 0.000206, "average": 0.99317, "min": 0.937162}, "location": {"width": 688, "top": 559, "height": 40, "left": 179}, "words": "阿昔替尼起始剂量。终末期肾病患者(CLcr<15mL/min)应慎用本品"}, {"probability": {"variance": 0.004329, "average": 0.978607, "min": 0.700945}, "location": {"width": 781, "top": 610, "height": 43, "left": 226}, "words": "肝损害:当轻度肝损害患者服用阿昔替尼时,无需调整起始剂量( Child-Pugh分级"}, {"probability": {"variance": 2.7e-05, "average": 0.997608, "min": 0.971193}, "location": {"width": 849, "top": 664, "height": 46, "left": 180}, "words": "A级)。根据药代动力学数据,当基线肝功能中度肝损害患者服用阿昔替尼时,起始剂"}, {"probability": {"variance": 0.006699, "average": 0.978969, "min": 0.527134}, "location": {"width": 847, "top": 718, "height": 46, "left": 182}, "words": "量应减半( Child-Pugh分级:B级)。可根据患者安全性和耐受性的个体差异增加或降"}, {"probability": {"variance": 0.003121, "average": 0.97714, "min": 0.682259}, "location": {"width": 845, "top": 775, "height": 43, "left": 185}, "words": "低随后剂量。目前尚未在重度肝损害( Child-Pugh分级:C级)患者中进行过阿昔替尼"}, {"probability": {"variance": 4e-06, "average": 0.998925, "min": 0.990747}, "location": {"width": 699, "top": 830, "height": 43, "left": 185}, "words": "研究,不应在该人群中使用阿昔替尼(见【注意事项】和【药代动力学"}, {"probability": {"variance": 0.050248, "average": 0.648034, "min": 0.423873}, "location": {"width": 78, "top": 835, "height": 48, "left": 894}, "words": "不"}, {"probability": {"variance": 0, "average": 0.999662, "min": 0.99904}, "location": {"width": 93, "top": 898, "height": 28, "left": 185}, "words": "儿童人群"}, {"probability": {"variance": 5e-06, "average": 0.998617, "min": 0.991893}, "location": {"width": 497, "top": 942, "height": 38, "left": 229}, "words": "尚未在儿童患者中研究阿昔替尼的安全性和有效性"}, {"probability": {"variance": 2e-06, "average": 0.998944, "min": 0.995562}, "location": {"width": 122, "top": 1004, "height": 28, "left": 193}, "words": "【不良反应】"}, {"probability": {"variance": 2e-05, "average": 0.997902, "min": 0.983618}, "location": {"width": 802, "top": 1046, "height": 45, "left": 229}, "words": "因为临床试验在各种不同条件下实施,因此一种药物在临床试验中观察到的不良反"}, {"probability": {"variance": 9e-06, "average": 0.998707, "min": 0.984345}, "location": {"width": 847, "top": 1101, "height": 43, "left": 185}, "words": "应发生率不能与另一种药物在临床试验中观察到的不良反应发生率进行直接比较,并且"}, {"probability": {"variance": 2.1e-05, "average": 0.998348, "min": 0.978433}, "location": {"width": 518, "top": 1160, "height": 39, "left": 187}, "words": "可能不能反映在临床实践中观察到的不良反应发生率"}, {"probability": {"variance": 9.6e-05, "average": 0.996416, "min": 0.943827}, "location": {"width": 802, "top": 1209, "height": 45, "left": 232}, "words": "在单药治疗研究的715例患者中评价了阿昔替尼的安全性,其中包括537例晚期"}, {"probability": {"variance": 0.00128, "average": 0.984304, "min": 0.839727}, "location": {"width": 847, "top": 1265, "height": 46, "left": 187}, "words": "RCC患者。所述数据反映了参加一项与索拉非尼相比的随机临床研究的359例晚期RCC"}, {"probability": {"variance": 5.2e-05, "average": 0.995044, "min": 0.970927}, "location": {"width": 454, "top": 1328, "height": 38, "left": 188}, "words": "患者服用阿昔替尼的安全性(见【临床试验】)"}, {"probability": {"variance": 2.5e-05, "average": 0.997987, "min": 0.970724}, "location": {"width": 802, "top": 1376, "height": 44, "left": 233}, "words": "将在说明书的其他章节中更详细地讨论以下风险,包括应采取的相应措施(见【注"}, {"probability": {"variance": 0.002342, "average": 0.988774, "min": 0.704268}, "location": {"width": 846, "top": 1431, "height": 46, "left": 189}, "words": "意事项】):高血压、动脉血栓栓塞事件、静脉血栓栓塞事件、出血、心力衰竭、胃肠穿"}, {"probability": {"variance": 1.2e-05, "average": 0.99527, "min": 0.99036}, "location": {"width": 130, "top": 1586, "height": 24, "left": 552}, "words": "第4页,共27页"}, {"probability": {"variance": 0.002586, "average": 0.932724, "min": 0.858448}, "location": {"width": 69, "top": 1617, "height": 21, "left": 250}, "words": "No:20150"}], "language": 3}